Abstract
First-, second-, and third-generation (G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are now available in clinical practice. Since acquisition of T790M and C797S mutations confer resistance to 1G/2G and 3G EGFR-TKIs, respectively, several 4G EGFR-TKIs that can inhibit triple mutations of activating mutation/T790M/C797S are now being developed. In this study, we evaluated an in vitro activity and potential resistance mutations to one of the 4G EGFR-TKIs, BI-4020, using Ba/F3 models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
